Pessac

• OCEAN(a)-CCTA - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction -Coronary Computed Tomography Angiography trial Recruiting
  2025-521117-88-00 5 2026-03-11 Cardiovascular Disease
• BEvacizumab plus Trifluridine/tipiracil in a bi-WEEkly administration to reduce grade 3-4 Neutropenia in patients with mCRC: A prospective, … Recruiting
  2024-520128-27-00 4 2026-03-04 colorectal adenocarcinoma
• Evaluation of efficacy and safety of early in hospital initiation of inclisiran treatment in patients with acute coronary syndromes Recruiting
  2025-521670-34-00 5 2026-03-04 Acute coronary syndrome (ST-elevation myocardial infarction [STEMI] or
• Phase 2b/3 Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide Recruiting
  2025-522015-42-00 10 2026-02-26 Chronic Hepatitis D Infection
• A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratum … Recruiting
  2025-520897-21-00 10 2026-02-25 Multiple Myeloma
• A trial to learn how safe Dato-DXd is and how well it works in people with NSCLC that has advanced after receiving osimertinib Recruiting
  2024-511362-37-00 5 2026-02-18 Non squamous non-small cell lung cancer (NSCLC)
• Lp(a) lowering study of pelacarsen (TQJ230) with background inclisiran in participants with elevated Lp(a) and established ASCVD Recruiting
  2024-516356-18-00 5 2026-02-17 Atherosclerotic cardiovascular disease (ASCVD)
• A Study to Evaluate Brenipatide Compared with Placebo in Adult Participants with Uncontrolled Moderate to Severe Asthma Recruiting
  2025-522640-41-00 4 2026-02-13 Asthma
• ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting
  2025-522960-34-00 5 2026-02-09 Established cardiovascular disease
• Tarlatamab vs standard of care chemotherapy in patients with pre-treated advanced, pulmonary or gastroenteropancreatic poorly differentiated … Recruiting
  2024-515948-23-00 5 2026-02-06 Advanced pulmonary or gastroenteropancreatic poorly differentiated neu
• A multicenter phase 2 single-arm proof-of-concept trial assessing the efficacy and safety of Obinutuzumab in the treatment of non-infectious … Recruiting
  2023-508930-33-00 4 2026-01-30 Non-infectious active cryoglobulinemia vasculitis who are either refra
• NUCastle - Nintedanib treatment in Unicentric Castleman disease Recruiting
  2023-510253-42-00 4 2026-01-28 Adult patients aged 18 and over with unicentric hyalino-vascular Castl
• FILOWM4-WaZaBi: "Open label phase 2 study evaluating the efficacy and tolerance of a zanubrutinib and BGB-11417 combination in patients prev … Recruiting
  2023-505781-28-00 4 2026-01-20 Patients with Waldenstrom macroglobulinemia and have received at least
• LA-HCM : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients with Abnormal Left Atrial Strain : A Randomized M … Recruiting
  2024-511084-28-00 11 2026-01-12 Hypertrophic Cardiomyopathie
• GRAALL 2024 - A 3-cohort Randomized Study evaluating the role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Tran … Recruiting
  2024-511437-35-00 10 2026-01-05 Patients aged 18-65 years old with newly diagnosed previously untreate
• Efficacy and Safety of Lisocabtagene Maraleucel (liso-cel) as First-Line Therapy in Adults with Transplant-Ineligible Primary Central Nervou … Recruiting
  2025-521144-38-00 4 2025-12-23 Primary Central Nervous System Lymphoma
• OBI-WAN : Obinutuzumab for remission induction in patients with relapsing PR3-ANCA granulomatosis with polyangiitis (Wegener’s). Phase 2 pro … Recruiting
  2022-501557-36-00 4 2025-12-19 PR3-ANCA granulomatosis with polyangiitis (Wegener’s)
• Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residua … Recruiting
  2024-512503-39-00 6 2025-12-19 Arm A (AML): Newly diagnosed de novo Acute myeloid leukemia (AML) or M
• A trial to learn how well AZD0292 works, how safe it is, and how it moves throughout the body over time in people with bronchiectasis and ch … Recruiting
  2025-523009-14-00 4 2025-12-16 Bronchiectasis with chronic pseudomonas aeruginosa colonization
• WIthdrawal of DUpilumab in Severe Asthma : a randomised non-inferiority-controlled trial Recruiting
  2024-516789-13-00 6 2025-12-15 Severe asthma
• Open label phase II study evaluating the efficacy and safety of the combination of tagraxofusp and venetoclax in treatment-naive blastic pla … Recruiting
  2024-511003-42-00 4 2025-12-11 BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASMS
• Study to Evaluate Plozasiran in Adults with Hypertriglyceridemia (SHASTA-10 Study) Recruiting
  2024-519712-13-00 5 2025-12-08 Hypertriglyceridemia (HTG)
• A 52-week study of rilzabrutinib efficacy and safety compared to placebo in adults diagnosed with IgG4-related disease Recruiting
  2025-521398-15-00 5 2025-12-04 Immune system diseases
• Efficacy and Safety of Icotrokinra in Adult and Adolescent Participants with Moderately to Severely Active Ulcerative Colitis Recruiting
  2025-521381-10-00 5 2025-12-03 Moderately to Severely Active Ulcerative Colitis

Showing 97–120 of 514 trials